Parkside Financial Bank & Trust Enanta Pharmaceuticals Inc Transaction History

Parkside Financial Bank & Trust

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$20.68 - $39.85 $1,985 - $3,825	96 Added 218.18%	140 $2,000
Q4 2022 Feb 13, 2023	SELL	$40.77 - $53.73 $611 - $805	-15 Reduced 25.42%	44 $2,000
Q3 2022 Nov 01, 2022	BUY	$48.29 - $71.27 $2,752 - $4,062	57 Added 2850.0%	59 $3,000
Q2 2022 Jul 13, 2022	SELL	$38.13 - $76.93 $2,249 - $4,538	-59 Reduced 96.72%	2 $0
Q1 2022 May 13, 2022	SELL	$56.06 - $74.11 $280 - $370	-5 Reduced 7.58%	61 $4,000
Q3 2021 Oct 29, 2021	SELL	$41.02 - $58.65 $82 - $117	-2 Reduced 2.94%	66 $4,000
Q2 2021 Aug 06, 2021	BUY	$43.76 - $53.11 $262 - $318	6 Added 9.68%	68 $3,000
Q1 2021 May 10, 2021	BUY	$41.69 - $54.95 $1,459 - $1,923	35 Added 129.63%	62 $3,000
Q4 2020 Feb 09, 2021	SELL	$41.16 - $47.47 $617 - $712	-15 Reduced 35.71%	27 $1,000
Q1 2020 May 05, 2020	BUY	$40.22 - $62.0 $925 - $1,426	23 Added 121.05%	42 $2,000
Q4 2019 Jan 30, 2020	SELL	$57.95 - $66.61 $405 - $466	-7 Reduced 26.92%	19 $1,000
Q1 2019 May 01, 2019	BUY	$69.08 - $105.66 $898 - $1,373	13 Added 100.0%	26 $2,000
Q3 2017 Oct 27, 2017	BUY	$37.91 - $46.8 $492 - $608	13	13 $1,000

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $177M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on Parkside Financial Bank & Trust with notifications on news.